GH vs. VCYT, RDNT, FTRE, VRDN, FLGT, CSTL, CLDX, RCKT, ASTH, and NTLA
Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Veracyte (VCYT), RadNet (RDNT), Fortrea (FTRE), Viridian Therapeutics (VRDN), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Celldex Therapeutics (CLDX), Rocket Pharmaceuticals (RCKT), Astrana Health (ASTH), and Intellia Therapeutics (NTLA). These companies are all part of the "medical" sector.
Veracyte (NASDAQ:VCYT) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.
Veracyte has a net margin of -20.61% compared to Veracyte's net margin of -85.02%. Guardant Health's return on equity of -2.02% beat Veracyte's return on equity.
Veracyte has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.
In the previous week, Guardant Health had 7 more articles in the media than Veracyte. MarketBeat recorded 12 mentions for Guardant Health and 5 mentions for Veracyte. Veracyte's average media sentiment score of 0.49 beat Guardant Health's score of 0.39 indicating that Guardant Health is being referred to more favorably in the news media.
Veracyte has higher earnings, but lower revenue than Guardant Health. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.
Veracyte received 167 more outperform votes than Guardant Health when rated by MarketBeat users. Likewise, 72.88% of users gave Veracyte an outperform vote while only 68.67% of users gave Guardant Health an outperform vote.
92.6% of Guardant Health shares are held by institutional investors. 2.6% of Veracyte shares are held by insiders. Comparatively, 6.2% of Guardant Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Veracyte presently has a consensus target price of $29.00, suggesting a potential upside of 48.87%. Guardant Health has a consensus target price of $39.27, suggesting a potential upside of 128.86%. Given Veracyte's stronger consensus rating and higher possible upside, analysts plainly believe Guardant Health is more favorable than Veracyte.
Summary
Veracyte and Guardant Health tied by winning 9 of the 18 factors compared between the two stocks.
Get Guardant Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardant Health Competitors List
Related Companies and Tools
